Phil Elstob

Commercialisation Director

Phil Elstob is a prominent figure in the field of technology transfer and commercialization, particularly within the life sciences sector. He currently serves as the Commercialisation Director at Cambridge Enterprise, where he focuses on bridging the gap between innovative technologies developed at the University of Cambridge and potential industry partners and investors. His work is particularly centered on the commercialization of new medicines and other life sciences technologies.1 2

Professional Background

Experience at Cancer Research Technology (CRT): Before joining Cambridge Enterprise in 2018, Phil spent 17 years at CRT, which is the commercialization arm of Cancer Research UK. He rose to the position of Head of Commercial Portfolio, where he was instrumental in establishing strategic partnerships, including a notable alliance with Newcastle University that facilitated significant advancements in cancer drug discovery.1 2
Leadership Roles: Phil has held leadership roles in various organizations, including serving as CEO of Demuris Limited, a spin-out company from Newcastle University focused on antibiotic drug discovery. His efforts have led to substantial funding initiatives, such as raising £3.4 million for PolyProx Therapeutics, another spin-out company he supported.1

Academic Credentials

Phil holds a PhD in developmental biology from the MRC’s National Institute for Medical Research (now part of the Francis Crick Institute). His academic background complements his professional endeavors, particularly in training and coaching within technology transfer roles.1 2

Contributions to Professional Development

In addition to his commercial activities, Phil has been actively involved in professional development through his role on PraxisAuril’s Professional Development Committee since 2013. He contributes to designing and delivering training courses aimed at enhancing skills in technology transfer and strategic partnerships.1 2

Phil Elstob's extensive experience in commercialization and his commitment to fostering innovation make him a key player in advancing life sciences technologies from research to market application.